Brief: Biomarin To Acquire Amicus Therapeutics For $4.8 Billion

BioMarin Pharmaceutical

19/12/2025 13:43

Dec 19 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O:

BIOMARIN TO ACQUIRE AMICUS THERAPEUTICS FOR $4.8 BILLION, EXPANDING POSITION AS A LEADER IN RARE DISEASES, ACCELERATING REVENUE GROWTH AND STRENGTHENING FINANCIAL OUTLOOK

AMICUS THERAPEUTICS INC - BIOMARIN TO BUY AMICUS FOR $14.50 PER SHARE IN CASH

AMICUS THERAPEUTICS INC - BIOMARIN TO FINANCE DEAL WITH CASH AND $3.7 BILLION DEBT

AMICUS THERAPEUTICS INC: DEAL EXPECTED TO BE ACCRETIVE TO NON-GAAP DILUTED EARNINGS PER SHARE  IN FIRST 12 MONTHS POST-CLOSE

AMICUS THERAPEUTICS INC: PENDING U.S. GALAFOLD IP LITIGATION RESOLVED

AMICUS THERAPEUTICS :  DEAL SUBSTANTIALLY ACCRETIVE TO NON-GAAP DILUTED EPS BEGINNING IN 2027 TO BIOMARIN

AMICUS THERAPEUTICS: ENTERED LICENSE AGREEMENTS WITH AUROBINDO & LUPIN FOR GALAFOLD 123 MG CAPSULES

AMICUS THERAPEUTICS: TO GRANT AUROBINDO AND LUPIN LICENSES TO MARKET GENERIC VERSIONS OF GALAFOLD IN US FROM JAN 30, 2037

Source text: ID:nPn6mkX9xa

Further company coverage: BMRN.O

 ((Reuters.Briefs@thomsonreuters.com;))